These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24908279)

  • 1. Association between allopurinol and mortality among Japanese hemodialysis patients: results from the DOPPS.
    Tsuruta Y; Nitta K; Akizawa T; Fukuhara S; Saito A; Karaboyas A; Li Y; Port FK; Robinson BM; Pisoni RL; Akiba T
    Int Urol Nephrol; 2014 Sep; 46(9):1833-41. PubMed ID: 24908279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease.
    Yelken B; Caliskan Y; Gorgulu N; Altun I; Yilmaz A; Yazici H; Oflaz H; Yildiz A
    Clin Nephrol; 2012 Apr; 77(4):275-82. PubMed ID: 22445470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population.
    Latif W; Karaboyas A; Tong L; Winchester JF; Arrington CJ; Pisoni RL; Marshall MR; Kleophas W; Levin NW; Sen A; Robinson BM; Saran R
    Clin J Am Soc Nephrol; 2011 Oct; 6(10):2470-7. PubMed ID: 21868616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum uric acid levels and long-term outcomes in chronic kidney disease.
    Miyaoka T; Mochizuki T; Takei T; Tsuchiya K; Nitta K
    Heart Vessels; 2014 Jul; 29(4):504-12. PubMed ID: 23929090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of hyperuricemia and serum uric acid lowering therapy with mortality in hemodialysis patients.
    Rohn B; Jansing W; Seibert FS; Pfab T; Cinkilic O; Paßfall J; Schmidt S; Babel N; Bauer F; Westhoff TH
    Ren Fail; 2020 Nov; 42(1):1067-1075. PubMed ID: 33076736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
    Sakai Y; Otsuka T; Ohno D; Murasawa T; Sato N; Tsuruoka S
    Ren Fail; 2014 Mar; 36(2):225-31. PubMed ID: 24152124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients.
    Bayram D; Tuğrul Sezer M; İnal S; Altuntaş A; Kıdır V; Orhan H
    Clin Exp Nephrol; 2015 Jun; 19(3):443-9. PubMed ID: 25082656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hyperuricemia and treatment for hyperuricemia in Japanese hemodialysis patients: A cohort study.
    Sugano N; Maruyama Y; Kidoguchi S; Ohno I; Wada A; Shigematsu T; Masakane I; Yokoo T
    PLoS One; 2019; 14(6):e0217859. PubMed ID: 31170241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
    Lee JW; Lee KH
    Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymptomatic hyperuricemia and cardiovascular mortality in patients with chronic kidney disease who progress to hemodialysis.
    Petreski T; Ekart R; Hojs R; Bevc S
    Int Urol Nephrol; 2019 Jun; 51(6):1013-1018. PubMed ID: 31020628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular Function and Uric Acid-Lowering in Stage 3 CKD.
    Jalal DI; Decker E; Perrenoud L; Nowak KL; Bispham N; Mehta T; Smits G; You Z; Seals D; Chonchol M; Johnson RJ
    J Am Soc Nephrol; 2017 Mar; 28(3):943-952. PubMed ID: 27620990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
    Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
    J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease　- Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
    Hisatome I; Li P; Miake J; Taufiq F; Mahati E; Maharani N; Utami SB; Kuwabara M; Bahrudin U; Ninomiya H
    Circ J; 2021 Jan; 85(2):130-138. PubMed ID: 33342914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.
    Tsuruta Y; Mochizuki T; Moriyama T; Itabashi M; Takei T; Tsuchiya K; Nitta K
    Clin Rheumatol; 2014 Nov; 33(11):1643-8. PubMed ID: 25048744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombocytopenia predicts mortality in Chinese hemodialysis patients- an analysis of the China DOPPS.
    Zhao X; Niu Q; Gan L; Hou FF; Liang X; Ni Z; Chen X; Chen Y; McCullough K; Robinson B; Zuo L
    BMC Nephrol; 2022 Jan; 23(1):11. PubMed ID: 34979949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status.
    Lopes AA; Tong L; Thumma J; Li Y; Fuller DS; Morgenstern H; Bommer J; Kerr PG; Tentori F; Akiba T; Gillespie BW; Robinson BM; Port FK; Pisoni RL
    Am J Kidney Dis; 2012 Jul; 60(1):90-101. PubMed ID: 22385781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
    Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of Allopurinol Treatment on Blood Pressure and Renal Function in Patients with Early Stage of Chronic Kidney Disease.
    Satirapoj B; Wirajit O; Burata A; Supasyndh O; Ruangkanchanasetr P
    J Med Assoc Thai; 2015 Dec; 98(12):1155-61. PubMed ID: 27004299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.